Clinical trial NCT02360696 - References

Dyspepsia — Functional Dyspepsia (FD) - Clinical Response to Montelukast in Children

Citation(s)

•   Aguillón JC, Cruzat A, Aravena O, Salazar L, Llanos C, Cuchacovich M
  Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution? Immunobiology. 2006;211(1-2):75-84. Epub 2005 Dec 27. Review.
•   Benjamini Y, Hochberg Y
  Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B 1995;57:289-300.
•   Bischoff SC, Lorentz A, Schwengberg S, Weier G, Raab R, Manns MP
  Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Gut. 1999 May;44(5):643-52.
•   Bizzintino JA, Khoo SK, Zhang G, Martin AC, Rueter K, Geelhoed GC, Goldblatt J, Laing IA, Le Souëf PN, Hayden CM
  Leukotriene pathway polymorphisms are associated with altered cysteinyl leukotriene production in children with acute asthma. Prostaglandins Leukot Essent Fatty Acids. 2009 Jul;81(1):9-15. doi: 10.1016/j.plefa.2009.05.022. Epub 2009 Jun 12.
•   Chiba M, Xu X, Nishime JA, Balani SK, Lin JH
  Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab Dispos. 1997 Sep;25(9):1022-31.
•   Daily EB, Aquilante CL
  Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep;10(9):1489-510. doi: 10.2217/pgs.09.82.
•   de Vries N, Tak PP
  The response to anti-TNF-alpha treatment: gene regulation at the bedside. Rheumatology (Oxford). 2005 Jun;44(6):705-7. Epub 2005 Apr 26.
•   Duroudier NP, Tulah AS, Sayers I
  Leukotriene pathway genetics and pharmacogenetics in allergy. Allergy. 2009 Jun;64(6):823-39. doi: 10.1111/j.1398-9995.2009.02015.x. Epub 2009 Mar 26. Review.
•   Efron B, Tibshirani R, Storey JD, Tusher V
  Empirical Bayes analysis of a microarray experiment. J Am Stat Assoc 2001;96:1151-1160.
•   Erjefält JS, Greiff L, Andersson M, Adelroth E, Jeffery PK, Persson CG
  Degranulation patterns of eosinophil granulocytes as determinants of eosinophil driven disease. Thorax. 2001 May;56(5):341-4.
•   Filppula AM, Laitila J, Neuvonen PJ, Backman JT
  Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. Drug Metab Dispos. 2011 May;39(5):904-11. doi: 10.1124/dmd.110.037689. Epub 2011 Feb 2.
•   Friesen CA, Andre L, Garola R, Hodge C, Roberts C
  Activated duodenal mucosal eosinophils in children with dyspepsia: a pilot transmission electron microscopic study. J Pediatr Gastroenterol Nutr. 2002 Sep;35(3):329-33.
•   Friesen CA, Kearns GL, Andre L, Neustrom M, Roberts CC, Abdel-Rahman SM
  Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. J Pediatr Gastroenterol Nutr. 2004 Mar;38(3):343-51.
•   Friesen CA, Lin Z, Singh M, Singh V, Schurman JV, Burchell N, Cocjin JT, McCallum RW
  Antral inflammatory cells, gastric emptying, and electrogastrography in pediatric functional dyspepsia. Dig Dis Sci. 2008 Oct;53(10):2634-40. doi: 10.1007/s10620-008-0207-0. Epub 2008 Mar 5.
•   Friesen CA, Neilan NA, Schurman JV, Taylor DL, Kearns GL, Abdel-Rahman SM
  Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterol. 2009 May 11;9:32. doi: 10.1186/1471-230X-9-32.
•   Friesen CA, Sandridge L, Andre L, Roberts CC, Abdel-Rahman SM
  Mucosal eosinophilia and response to H1/H2 antagonist and cromolyn therapy in pediatric dyspepsia. Clin Pediatr (Phila). 2006 Mar;45(2):143-7.
•   Hall W, Buckley M, Crotty P, O'Morain CA
  Gastric mucosal mast cells are increased in Helicobacter pylori-negative functional dyspepsia. Clin Gastroenterol Hepatol. 2003 Sep;1(5):363-9.
•   Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT
  Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin Pharmacol Ther. 2010 Aug;88(2):223-30. doi: 10.1038/clpt.2010.73. Epub 2010 Jun 30.
•   Kazani S, Wechsler ME, Israel E
  The role of pharmacogenomics in improving the management of asthma. J Allergy Clin Immunol. 2010 Feb;125(2):295-302; quiz 303-4. doi: 10.1016/j.jaci.2009.12.014. Review.
•   Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE
  Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med. 2003 Sep 18;349(12):1157-67. Review.
•   Kim SH, Yang EM, Kim SH, Park HS
  Regulation of monocyte chemoattractant protein 1 by cysteinyl leukotriene D4 in human lung epithelial A549 cells. Ann Allergy Asthma Immunol. 2009 Oct;103(4):358-9. doi: 10.1016/S1081-1206(10)60540-6.
•   Knorr B, Larson P, Nguyen HH, Holland S, Reiss TF, Chervinsky P, Blake K, van Nispen CH, Noonan G, Freeman A, Haesen R, Michiels N, Rogers JD, Amin RD, Zhao J, Xu X, Seidenberg BC, Gertz BJ, Spielberg S
  Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults. J Clin Pharmacol. 1999 Aug;39(8):786-93.
•   Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG, Allayee H, Wang J, Sylvester J, Holbrook J, Wise R, Weiss ST, Barnes K
  Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 2006 Feb 15;173(4):379-85. Epub 2005 Nov 17.
•   Lima JJ
  Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. Mol Diagn Ther. 2007;11(2):97-104. Review.
•   Maeba S, Ichiyama T, Ueno Y, Makata H, Matsubara T, Furukawa S
  Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules. Ann Allergy Asthma Immunol. 2005 Jun;94(6):670-4.
•   Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ
  Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009 Feb;19(2):129-38. doi: 10.1097/FPC.0b013e32831bd98c.
•   Mougey EB, Lang JE, Wen X, Lima JJ
  Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J Clin Pharmacol. 2011 May;51(5):751-60. doi: 10.1177/0091270010374472. Epub 2010 Oct 25.
•   Muijsers RB, Noble S
  Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age. Paediatr Drugs. 2002;4(2):123-39. Review.
•   Neustrom MR, Friesen C
  Treatment of eosinophilic gastroenteritis with montelukast. J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):506.
•   Peters-Golden M, Gleason MM, Togias A
  Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy. 2006 Jun;36(6):689-703. Review.
•   Rodríguez-Antona C, Niemi M, Backman JT, Kajosaari LI, Neuvonen PJ, Robledo M, Ingelman-Sundberg M
  Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J. 2008 Aug;8(4):268-77. Epub 2007 Oct 9.
•   Sampson AP, Pizzichini E, Bisgaard H
  Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation. J Allergy Clin Immunol. 2003 Jan;111(1 Suppl):S49-59; discussion S59-61. Review.
•   Schurman JV, Danda CE, Friesen CA, Hyman PE, Simon SD, Cocjin JT
  Variations in psychological profile among children with recurrent abdominal pain. J Clin Psychol Med Settings. 2008 Sep;15(3):241-51. doi: 10.1007/s10880-008-9120-0. Epub 2008 Jul 25.
•   Schurman JV, Singh M, Singh V, Neilan N, Friesen CA
  Symptoms and subtypes in pediatric functional dyspepsia: relation to mucosal inflammation and psychological functioning. J Pediatr Gastroenterol Nutr. 2010 Sep;51(3):298-303. doi: 10.1097/MPG.0b013e3181d1363c.
•   Schwartz DA, Pardi DS, Murray JA
  Use of montelukast as steroid-sparing agent for recurrent eosinophilic gastroenteritis. Dig Dis Sci. 2001 Aug;46(8):1787-90.
•   Singh RK, Gupta S, Dastidar S, Ray A
  Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology. 2010;85(6):336-49. doi: 10.1159/000312669. Epub 2010 Jun 2. Review.
•   Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V
  Functional gastroduodenal disorders. Gastroenterology. 2006 Apr;130(5):1466-79. Review. Erratum in: Gastroenterology. 2006 Jul;131(1):336.
•   Talley NJ, Walker MM, Aro P, Ronkainen J, Storskrubb T, Hindley LA, Harmsen WS, Zinsmeister AR, Agréus L
  Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1175-83. Epub 2007 Aug 7.
•   Tusher VG, Tibshirani R, Chu G
  Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21. Epub 2001 Apr 17. Erratum in: Proc Natl Acad Sci U S A 2001 Aug 28;98(18):10515.
•   Vanderhoof JA, Young RJ, Hanner TL, Kettlehut B
  Montelukast: use in pediatric patients with eosinophilic gastrointestinal disease. J Pediatr Gastroenterol Nutr. 2003 Feb;36(2):293-4.
•   Zanger UM, Turpeinen M, Klein K, Schwab M
  Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008 Nov;392(6):1093-108. doi: 10.1007/s00216-008-2291-6. Epub 2008 Aug 10. Review.

Predictors of Clinical Response to Montelukast in Children With Functional Dyspepsia

Details for clinical trial NCT02360696